Saliva Drug Screening in W.A. Correctional Settings. Hayley Taylor Kati Kraszlan Christine Anderton May – October 2004. Department of Justice. Feb 2003 DoJ hosted the Drugs Roundtable Forum. - Justice Drug Plan developed – reduce drug demand/supply/harm in Prisons.
May – October 2004
- Justice Drug Plan developed – reduce drug demand/supply/harm in Prisons.
- Conduct a review of drug testing technologies.
- reviewed drug testing technologies and determined those viable for use within correctional settings. Investigated hair, sweat, saliva, urine.
- the report indicated that the use of saliva for drug detection may have some validity in a correctional setting and required further investigation.
- Relatively non-invasive
- Easily accessible
- Unlikely to be susceptible to adulteration
(10 minute saliva turnover rate)
- No requirement for specialised venues
- Either gender can supervise
- On-site results in a matter of minutes
2) Hakea – Maximum Prison
3) Wooroloo – Minimum Prison Farm
*** All of the offenders/prisoners and officers that participated in the trial completed a brief questionnaire to determine attitudes towards saliva drug testing.
(Bioscience Ltd, Abingdon Oxfordshire UK)
- 73.7% male
(UltiMed Products GmBh, Ahrensburg, Germany)
- 72.7% male
** Hakea/Acacia target was not achieved
No Cocaine positives recorded
Methadone positives were prescription based
A total of 15.5% of saliva tests at DC and 3.02% of saliva tests at Prisons tested positive for an illicit drug.
A total of 12.7% of saliva tests at DC and 2.4% at Prisons tested positive for an illicit drug.
Attitude data combined for the two saliva products
- 87.7% less time to collect saliva sample compared to urine sample
- 82.4% prefer to collect a saliva sample rather than a urine sample
- Advantages of saliva testing: both genders can supervise, testing is less intrusive, quicker, easier and negates time involved with strip searches.
- Disadvantages of saliva testing: window of detection, limited number of drugs detected and urine still had to be collected.
Please contact Christine Anderton for any further information concerning Drug Strategies within the Department of Justice.
Phone: 9278 1048